Paromomycin sulfate warnings and precautions

Revision as of 20:40, 23 December 2013 by Gerald Chi (talk | contribs)
Jump to navigation Jump to search
Paromomycin Sulfate
PAROMOMYCIN SULFATE capsule®
FDA Package Insert
Description
Clinical Pharmacology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Precautions

The use of this antibiotic, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. Constant observation of the patient is essential. If new infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken. The drug should be used with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption. This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.[1]

References

  1. "PAROMOMYCIN SULFATE CAPSULE [CARACO PHARMACEUTICAL LABORATORIES, LTD.]".

Adapted from the FDA Package Insert.